Acacia Pharma Raises £15 Million ($23.5 Million) to Advance Clinical Development of Lead Products for Supportive Care

     Acacia Pharma Raises £15 Million ($23.5 Million) to Advance Clinical
               Development of Lead Products for Supportive Care

  PR Newswire

  CAMBRIDGE, England, September 3, 2013

CAMBRIDGE, England, September 3, 2013 /PRNewswire/ --

Acacia Pharma, a pharmaceutical company specialising in the development of
drugs for supportive care, announces it has raised £15 million (~$23.5
million) in a Series B financing led by Fidelity Biosciences and Novo A/S.
Current investors Gilde Healthcare and Lundbeckfond Ventures also participated
in the round. Dr Alex Pasteur of Fidelity Biosciences and Dr Martin Edwards of
Novo A/S have joined the Board of Acacia Pharma as Non-executive Directors.

Acacia Pharma will use the proceeds to:

  *complete Phase III development of APD421 for the prevention of
    post-operative nausea & vomiting (PONV);
  *complete Phase II development of APD403 for the prevention of chemotherapy
    induced nausea & vomiting (CINV); and
  *develop the commercial presentation of APD515 for the treatment of
    xerostomia (dry mouth) in advanced cancer patients.

"I am delighted to welcome Fidelity and Novo to the Company and would like to
thank Gilde and Lundbeckfond for their continued support," commented Dr Julian
Gilbert, Acacia Pharma's CEO. "The Company is about to initiate a number of
key studies with results being available in 2014. The data generated to date
in PONV, CINV and xerostomia have been excellent; therefore we look forward to
continued success."

Dr Alex Pasteur of Fidelity Biosciences added, "Significant numbers of
post-surgical patients do not receive adequate nausea and vomiting
prophylaxis. APD421, Acacia Pharma's lead product, a D [2] /D [3] antagonist,
showed excellent efficacy in its Phase II trial, and had a very good safety
profile. We believe that a drug with this novel mechanism and displaying these
characteristics can provide a major contribution to the care of post-surgical

Dr Martin Edwards of Novo A/S stated, "In addition to APD421, Acacia Pharma
has generated excellent Phase II a proof-of-concept data on APD403 in CINV.
The drug, the same D [2] /D [3] antagonist used in APD421, appears to have a
unique anti-nauseant profile and can be added to current recommended CINV
regimens due to its novel, complementary, mechanism of action, thereby
targeting the key unmet need within this debilitating condition. We have high
hopes for APD403 and for the future success of the Company."

About Acacia Pharma

Acacia Pharma ( ) is a pharmaceutical company
focused on supportive care, a significant commercial opportunity. Growth in
the cancer supportive care market has been driven by the increasing incidence
of cancer, the expansion of effective cancer therapies and the desire to
improve both the effectiveness of treatment and the quality of life of cancer

Acacia Pharma has generated a pipeline of product opportunities addressing a
range of supportive care indications such as nausea & vomiting, xerostomia and
cachexia using a commercially driven approach to product discovery based on
known drugs. This strategy leads to product opportunities with a higher
probability of success and enables rapid clinical proof-of concept. In
addition, Acacia Pharma's products are expected to reach the market quickly
given that they are based on the novel use of well-characterised

Acacia Pharma is led by an experienced management team who have already
successfully built and exited life sciences companies. Management, Gilde
Healthcare Lundbeckfond Ventures, Fidelity Biosciences and Novo Ventures are
the Company's key shareholders. Acacia Pharma is based in Cambridge, UK.

About Fidelity Biosciences

Fidelity Biosciences ( ) invests venture
capital in biopharmaceutical, medical technology, healthcare information
technology and healthcare service companies. The firm is a subsidiary of FMR
LLC, the parent company of Fidelity Investments, one of the world's leading
providers of financial services. For more than 40 years, Fidelity has been a
significant presence in the venture capital and private equity industry. For
more information, visit the website above.

About Novo A/S

Novo ( ) .is the holding company of the Novo Group, and is
wholly owned by the Novo Nordisk Foundation. It was established in 1999 to
manage the assets of the foundation and actively make investments on its
behalf. Novo Ventures focuses on life sciences venture capital, and is active
in both Europe and North America. The firm has four partners in Copenhagen,
one in London and four in San Francisco. With an evergreen structure, it
annually invests approximately $150 million in venture capital into private
and public life sciences companies.

About Lundbeckfond Ventures

Lundbeckfond Ventures ( ) is an evergreen
life science venture fund investing in companies in Europe and in the US. It
is financially driven and invests primarily in drug development, as well as in
medtech. Lundbeckfond Ventures is part of the asset management subsidiary of
the Lundbeck Foundation which in addition to substantial financial assets has
controlling ownerships in H. Lundbeck A/S, ALK-Abelló A/S and Falk A/S.

About Gilde Healthcare  Gilde Healthcare (Utrecht, The Netherlands and
Cambridge, USA) is a transatlantic growth capital investor focused on private
healthcare companies. It has over €450 million ($600 million) under management
and is actively looking to lead new investments in therapeutics, diagnostics,
medical devices and healthcare services.

For a list of Gilde's portfolio companies please visit the website at .

Contact: Contacts: Acacia Pharma, Julian Gilbert, Telephone: +44-1223-875132;
Citigate Dewe Rogerson, David Dible or Mark Swallow, Telephone:
+44-20-7638-9571; Fidelity Biosciences, Alex Pasteur, Telephone:
+44-20-7074-5631; Novo A/S, Martin Edwards, Telephone: +44-7802-893240
Press spacebar to pause and continue. Press esc to stop.